DSM Biomedical entered into six multi-year licensing agreements with medical device manufacturers in the orthopedic, cardiovascular and urology fields this year.

The new licensees will employ DSM’s biomedical materials, including Bionate PCU, CarboSil TSPCU and ComfortCoat medical coatings in applications such as total disk replacement, spinal stabilization, continuous glucose monitoring, cardiac rhythm management, neurostimulation, catheters and heart assist devices, according to the company.

The Berkeley, Calif.-based medical device materials provider‘s Dutch parent Royal DSM N.V. posted net earnings of €149 million, or €0.90 per diluted share, on revenue of €2.27 billion during the three months ended June 30. That compares with net earnings of €10 million, or €0.05 per diluted share, on sales of €1.77 billion during the same period last year.